FCP

Falfurrias Capital Partners Announces Growth Investment in Brainlabs

Retrieved on: 
Monday, September 18, 2023
LLP, FCP, Partnership, Marketing, Culture, Livingbridge, Ad Council, WeTransfer, Cooley, Falfurrias, Texas, Investment, Growth, Adidas, Brainlab

CHARLOTTE, N.C., Sept. 18, 2023 /PRNewswire/ -- Falfurrias Capital Partners (FCP), a private equity firm focused on growth-oriented, middle-market businesses, today announced its investment in Brainlabs, an internationally acclaimed full-service media agency. The agency is renowned for its 'high-performance' approach to media, to deliver measurable and profitable business impact to brands worldwide, powered by data and technology.

Key Points: 
  • CHARLOTTE, N.C., Sept. 18, 2023 /PRNewswire/ -- Falfurrias Capital Partners (FCP), a private equity firm focused on growth-oriented, middle-market businesses, today announced its investment in Brainlabs , an internationally acclaimed full-service media agency.
  • In the four years since, the agency has seen top line growth of 800% and integrated eight strategic acquisitions.
  • Falfurrias Capital Partners' Alexander Jutkowitz, Geordie Pierson, and Joe Price, as well as the Ad Council's Lisa Sherman will join the company board.
  • "With our extensive experience in the marketing and media space, Brainlabs is a perfect fit for Falfurrias," said Geordie Pierson, Partner at Falfurrias Capital Partners.

Baseus Launches Let's C Chargers for the New Phone

Retrieved on: 
Wednesday, September 13, 2023
Carl C. Cable, PPS, Plastic, FCP, Data-rate units, AFC, PD, MacBook, Electronics, Eco-friendly dentistry, 100W, GB, Nature, Elevate, USB4, Apple ProRes, Apple, Pro, Electric battery, Television, Mobile phone

Alongside, the Baseus Habitat USB-C to USB-C Cable 100W is designed with eco-friendliness, using bio-based materials, replacing plastics with cornstarch up to 42% -- Baseus' first-ever biodegradable charging cable. This cable is available in pastel green & pink and features a microdot design that evokes nature. It has been tested to withstand over 10,000 bends and supports 100W fast charging, making it a versatile option for the new iPhone 15 lineup and MacBook.

Key Points: 
  • It includes fast chargers, power banks, charging cables, digital power strips, and car chargers for the iPhone 15.
  • Alongside, the Baseus Habitat USB-C to USB-C Cable 100W is designed with eco-friendliness, using bio-based materials, replacing plastics with cornstarch up to 42% -- Baseus' first-ever biodegradable charging cable.
  • Baseus Let's C Portable Charger is a 15W magnetic charging power bank with a PD 30W built-in charging cable, supporting 2-way fast charging.
  • Baseus Let's C Cable , the "Free2Draw" USB-C to C mini retractable cable 100W, features Baseus' patented mechanism, allowing anyone to pull out the cable exceptionally smooth and stepless to any length within its maximum range.

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

Retrieved on: 
Wednesday, August 23, 2023
FCP, Drug development, Moses Austin, University, College, Pharming, Teaching, Betaxolol, Clementi, Worldwide, Agent handling, GCP, Research, Biomedical sciences, Zolpidem, Boston University, CDO, University of Texas Health Science Center at San Antonio, EMA, University of Florida College of Pharmacy, CGMP, Sanofi, Patient, DBA, Fellow, IND, Faculty, Growth, FDA, Pharmacology, NIH, Pharmaceutical industry, Nursing, Tiziana, Medicine

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.

Key Points: 
  • NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer.
  • His deep understanding of drug development and his strategic insights will be invaluable as Tiziana continues to advance its pipeline.
  • Commenting on his new role, William A. Clementi said, "I am excited to join Tiziana Life Sciences and contribute to the advancement of its innovative therapeutic candidates.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, expressed his enthusiasm about the appointment, stating, "We are delighted to welcome William to Tiziana as our Chief Development Officer.

FCP Mezzanine Publishes a Construction Specifications Institute (CSI) Specification for Their Modular Mezzanine System

Retrieved on: 
Tuesday, August 22, 2023
FCP, IBC, ASPE, International Building Code, Construction Specifications Institute, Free-space optical communication, Name, CBC, Spec, AISI, Society, CSI, Safety, Cargo, Warehouse

VENTURA, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- FCP Mezzanine, a leading manufacturer of industrial steel mezzanines, elevated work platforms, and related safety components, is pleased to announce the publication of their Construction Specifications Institute (CSI) spec document for modular mezzanines. Now building contractors, architects, and other construction industry professionals can easily incorporate FCP's proprietary Free-Space Mezzanine™ system into their designs and cost proposals.

Key Points: 
  • FCP Mezzanine announces their CSI Spec publication for their proprietary Free-Space Mezzanines™, a modular mezzanine structure featuring FCP's exclusive ConnectRite™ connection system.
  • VENTURA, Calif., Aug. 22, 2023 /PRNewswire-PRWeb/ -- FCP Mezzanine , a leading manufacturer of industrial steel mezzanines , elevated work platforms, and related safety components, is pleased to announce the publication of their Construction Specifications Institute (CSI) spec document for modular mezzanines .
  • Now building contractors, architects, and other construction industry professionals can easily incorporate FCP's proprietary Free-Space Mezzanine™ system into their designs and cost proposals.
  • The CSI Modular Mezzanine CSI Spec document is free to download and doesn't require any pre-signup or commitment.

Reconnecting in Cupertino: FMC in cooperation with Apple Present FCP Creative Summit 2023

Retrieved on: 
Friday, August 11, 2023
Return, Learning, FCP, Final Cut Pro, IPad, Hyatt Regency Houston, Final Cut, Creativity, Certification, Apple, FMC, Growth, Environment, Mac, Software, Tourism

CUPERTINO, Calif., Aug. 11, 2023 /PRNewswire-PRWeb/ -- With immense anticipation and excitement, FMC, supported by Apple, proudly unveils the 2023 Final Cut Pro Creative Summit, which will take place on November 6, 7, and 8. The summit returns to Cupertino - a recognized hub of innovation - for the first time since 2019 and is set to be a momentous occasion. Building on the resounding success of last year's Final Cut Pro Summit roadshow, this eagerly-awaited event aims to foster collaboration and inspire boundless creativity in video editing.

Key Points: 
  • FMC Collaborates with Apple for the Return of the FCP Creative Summit to Cupertino: November 6,7 and 8.
  • CUPERTINO, Calif., Aug. 11, 2023 /PRNewswire-PRWeb/ -- With immense anticipation and excitement, FMC, supported by Apple, proudly unveils the 2023 Final Cut Pro Creative Summit, which will take place on November 6, 7, and 8.
  • The summit's kickoff allows attendees an unparalleled opportunity to discover the Apple campus and engage with the esteemed Apple team.
  • Join us this November to celebrate the exciting revival of the FCP Creative Summit in Cupertino.

Standard Solar Acquires Community Solar Project from New Columbia Solar; Bolsters Ownership Portfolio in Maryland

Retrieved on: 
Tuesday, August 8, 2023
Commercial Building & Real Estate, Utilities, Construction & Property, Environment, Alternative Energy, Energy, Environmental Health, Residential Building & Real Estate, FCP, Housing, Life, Electricity, Carbon, Government, Holly, NCS, Coal, Engineering, Solar energy, Standard solar model, News, Renewable energy

Standard Solar , a leader in the ownership, operation, funding and development of commercial and community solar assets, today announced it has acquired a community solar project at FCP®’s Holly Spring Meadows apartment community in Forestville, Md.

Key Points: 
  • Standard Solar , a leader in the ownership, operation, funding and development of commercial and community solar assets, today announced it has acquired a community solar project at FCP®’s Holly Spring Meadows apartment community in Forestville, Md.
  • The 800-kilowatt (kW) carport array and a 921-kW rooftop array project, along with 24 other projects owned by Standard Solar in the state, will help Maryland achieve its Renewable Portfolio Standard.
  • The Holly Spring Meadows community solar project stands as a great example of how solar energy can truly make a difference.
  • “This community solar project supports FCP’s robust energy savings strategies and reduces the overall carbon footprint of the community.

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

Retrieved on: 
Thursday, July 27, 2023
DED, FCP, Drug development, Moses Austin, University, Therapy, College, Pharming, Teaching, Biotechnology, Betaxolol, Clementi, Worldwide, NDA, GCP, Agent handling, Lead, Research, Biomedical sciences, Zolpidem, Boston University, University of Texas Health Science Center at San Antonio, EMA, Telecanthus, University of Florida College of Pharmacy, CGMP, Sanofi, DBA (airline), Fellow, IND, Faculty, Growth, FDA, Pharmacology, NIH, Pharmaceutical industry, Nursing, Medicine

Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.

Key Points: 
  • Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team.
  • In 1991 Dr. Clementi established a regulatory consulting company, Clementi & Associates, Ltd. (dba as Clementi Ltd).
  • "We are delighted to welcome William Clementi to OKYO Pharma as our new Chief Operating Officer.
  • Dr. Clementi's appointment comes at a crucial time for OKYO Pharma, with significant milestones on the horizon.

Jacksonville Electric Authority (JEA) Launches Fleet Electrification Program for C&I Fleets Implemented by Resource Innovations

Retrieved on: 
Wednesday, July 26, 2023
FCP, EV, Light, Transport, History, Kilowatt-hour, Growth, European Space Resources Innovation Centre, Vehicle registration plates of Nepal, TCO, JEA, Online shopping

The JEA Fleet Electrification Program is a turnkey program that has a service offering for all JEA C&I customers with fleet vehicles, regardless of fleet size or type, which will provide or assist customers with the development of a comprehensive Fleet Conversion Plan (FCP) and aid customers who move forward with the implementation of fleet electrification.

Key Points: 
  • The JEA Fleet Electrification Program is a turnkey program that has a service offering for all JEA C&I customers with fleet vehicles, regardless of fleet size or type, which will provide or assist customers with the development of a comprehensive Fleet Conversion Plan (FCP) and aid customers who move forward with the implementation of fleet electrification.
  • As a testament to their commitment, JEA's own fleet is leading by example and will be the first to finalize their fleet conversion plan.
  • "We are thrilled to collaborate with JEA on their Fleet Electrification Program," said Kelly Helfrich, VP of Transportation Electrification at Resource Innovations.
  • For more information about the JEA Fleet Electrification Program, please visit jea.com/fleetelectrification or contact [email protected] .

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, FDA, Health, Genetics, Pharmaceutical, Vaccine, Acceleration, Biologics license application, FCP, Diversified Specialty Institute Holdings, Inc., Therapy, Arcturus Therapeutics, Infection, ARCT, MBA, Medicine, RNA, MD, OTC, Liver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Arcturus

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ARCT-810, the Company’s mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
  • Fast Track Designation is designed to facilitate development and expedite review of new therapeutics intended to treat serious or life-threatening conditions that demonstrate the potential to address important unmet medical needs.
  • Programs granted Fast Track Designation may receive important benefits including more frequent interactions with FDA review teams and the ability to obtain rolling review of a Biologics License Application (BLA).
  • “ARCT-810 has the potential to be an important new medicine for individuals living with OTC deficiency and we are very pleased to have obtained Fast Track Designation for this program.

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Biometrics, Other Science, Research, Science, Clinical Trials, Mayo, Myelocyte, Maintenance, FCP, Drug development, TNF, AE, IBD, NDA, A.I, Lupus, Ulcerative colitis, Psoriasis, Open-label trial, LANCL2, US, Acquisition, UC, Patient, Kelly Gebo, New Drug Application, Pharmaceutical industry, Phosphorus

Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.

Key Points: 
  • Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.
  • Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, said, "Following our successful acquisition of the LANCL therapeutic portfolio, we have made meaningful progress in advancing our clinical development programs for omilancor in IBD and NIM-1324 in lupus.
  • Importantly, the omilancor program has taken just over four years since inception to reach Phase 3 initiation, representing significant cost savings compared to traditional drug development timelines.
  • PACIFY II aims to randomize 652 active disease UC patients, with 326 patients receiving 440mg of omilancor and 326 patients receiving placebo.